Partnership tra Nimbus Discovery e Schrödinger.

Il sito di Nimbus Discovery spiega in dettaglio l’importante accordo stipulato tra Nimbus Discovery e Schrödinger: “Nimbus Discovery is applying advances in computer-based drug discovery to unlock fundamental biological pathways.  Nimbus has already delivered selective, potent, and differentiated compounds within the first year for two disease targets, IRAK4 and ACC, which are pivotal to the progression of an aggressive subtype of non-Hodgkin’s lymphoma and obesity, respectively.  Over the next 12-18 months, Nimbus will identify clinical candidates for these targets and will expand its pipeline to include a new series of important targets. In 2010, Nimbus established a strategic partnership with Schrödinger, the leader in chemical simulation and in silico drug discovery, that grants Nimbus privileged access to leading-edge technology and exclusive rights to key targets. Under the terms of the agreement established in 2010, Nimbus will receive unique access to capabilities and technologies including exclusive rights to exploit cutting-edge next-generation WaterMap™ and related technologies against specific Nimbus targets, exclusive use of customized software packages developed by Schrödinger for these targets, and access to a dedicated team of Schrödinger computational chemists.”